In vivo and in vitro studies have demonstrated that FEN1 is frequently overexpressed in various cancers, such as breast cancer, glioma, and hepatocellular cancer, and that its upregulation promotes tumorigenesis and cancer progression[47–50]. This evidence concerns the gene FEN1 and breast cancer.